Yat Sun Or
2015
In 2015, Yat Sun Or earned a total compensation of $1.7M as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 22% increase compared to previous year.
Compensation breakdown
| Bonus | $151,030 |
|---|---|
| Option Awards | $1,078,330 |
| Salary | $374,825 |
| Stock Awards | $96,762 |
| Other | $15,706 |
| Total | $1,716,653 |
Or received $1.1M in option awards, accounting for 63% of the total pay in 2015.
Or also received $151K in bonus, $374.8K in salary, $96.8K in stock awards and $15.7K in other compensation.
Rankings
In 2015, Yat Sun Or's compensation ranked 5,349th out of 13,638 executives tracked by ExecPay. In other words, Or earned more than 60.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,349 out of 13,638 | 61st |
Division Manufacturing | 1,980 out of 5,187 | 62nd |
Major group Chemicals And Allied Products | 717 out of 1,857 | 61st |
Industry group Drugs | 570 out of 1,531 | 63rd |
Industry Pharmaceutical Preparations | 447 out of 1,179 | 62nd |
Source: SEC filing on January 6, 2017.
Or's colleagues
We found two more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2015.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019